NK cells plus atezolizumab for acute myeloid leukemia
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests combining natural killer (NK) immune cells with an immunotherapy drug (atezolizumab) for people with acute myeloid leukemia (AML) that didn't respond to or came back after prior treatments. It aims to see if this combination can help the body fight the leukemia.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 70 years old.
- You have AML that didn't improve after at least two prior treatments, or came back within 6 months of remission.
- You have a family member who is a partial tissue match and can donate blood cells (NK cells).
- You are generally in good health, with good heart, lung, kidney, and liver function.
- You have not had a stem cell transplant from another person before.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a treatment using natural killer (NK) cells combined with antibodies to fight a type of blood cancer called acute myeloid leukemia (AML). It is for people whose AML has come back or not improved with standard treatments.
This Phase 1/2 trial tests a lab-made immune-cell treatment (NK cells) for children with acute myeloid leukemia (AML) that has come back or did not respond to treatment. It aims to help the immune system attack leukemia cells in the bone marrow, especially when standard treatments have not worked.
This trial tests a new treatment using immune cells (called natural killer cells) derived from stem cells to help fight AML that has returned or not responded to standard therapy. The goal is to see if these cells can safely and effectively control the leukemia.
This trial tests whether giving specially trained natural killer (NK) cells after a stem cell transplant can help prevent relapse in people with high-risk blood cancers like AML, MDS, or MDS/MPN. You receive one infusion of these cells about a week after your transplant.
This trial tests a new type of immunotherapy using special immune cells (NK cells) that target the CD123 marker found on AML cells. It may help people whose AML has not responded to standard treatments and who have a healthy donor available.
This study tests whether adding natural killer (NK) cell infusions to standard consolidation chemotherapy helps keep acute myeloid leukemia (AML) in remission. It's for people with AML who are already in remission after their first treatment.
Hear when a new Acute Myeloid Leukemia, in Relapse trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.